5th Treg Summit

Kongressthemen
With investment into the Treg field at an all time high, excitement is overflowing at the prospect of these remarkable cells being game-changers in the long-term treatment of autoimmunity, inflammation and transplantation. As this enthusiasm coincides with multiple clinical readouts and several more therapies entering the clinic, it remains vital for Treg trailblazers to come together to recognize therapy efficacy, determine safety and translate the next-generation of therapies into the clinic.

Wissenschaftliche Fach-Gesellschaft
Hanson Wade

Anmerkungen
Speakers: Ali Zarrin, Vice President and Head of Discovery, TrexBio, Alison Budelsky, Head of Immunology Discovery, Eli Lilly, Anish Suri, President and Chief Scientific Officer, Cue Biopharma and More.

https://go.evvnt.com/1558199-2?pid=4832

Frau Molly Sullivan